MRNA technology takes on autoimmune diseases in new trial
NCT ID NCT07362758
First seen Jan 25, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This early-phase study tests a new mRNA therapy for people with severe autoimmune diseases like lupus or immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that targets and clears harmful B cells. The goal is to control the disease and reduce symptoms, but ongoing management may still be needed. About 47 participants aged 14 to 70 will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.